Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Lowe

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Plos Medicine|October 19, 2022
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19David M Lowe, Li-An K Brown, Kashfia Chowdhury, et al.
Frontiers in Immunology|July 26, 2024
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023)Samya Van Coillie, Johan Prévot, Silvia Sánchez-Ramón, et al.
The Journal of Allergy and Clinical Immunology|November 15, 2021
Treatment of chronic or relapsing COVID-19 in immunodeficiencyLi-An K Brown, Ed Moran, Anna Goodman, et al.
Clinical and Experimental Immunology|August 26, 2025
Immunophenotyping of apparently immunocompetent hosts with cryptococcosis reveals IL-17 deficiency as a unifying susceptibility factorKatie Townsend, Shichina Kannambath, Grant Hayman, et al.
Clinical Immunology (Orlando, Fla.)|January 13, 2024
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patientsAlexandra Y Kreins, Emma Roux, Juanita Pang, et al.
The Journal of Allergy and Clinical Immunology|August 16, 2019
A comprehensive characterization of chronic norovirus infection in immunodeficient hostsLi-An K Brown, Christopher Ruis, Ian Clark, et al.
Frontiers in Immunology|March 18, 2026
Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotypeAidan Jia Sheng Yu, Fernando Moreira, Andrew Symes, et al.
Frontiers in Immunology|October 10, 2022
Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experienceAdrian M Shields, Susan Tadros, Adam Al-Hakim, et al.
Journal of Clinical Immunology|April 14, 2022
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD StudyAdrian M Shields, Sian E Faustini, Harriet J Hill, et al.
The Journal of Infection|May 21, 2025
Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR studyJudith Breuer, Myriam Drysdale, Jill Walker, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Plos Medicine|October 19, 2022
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19David M Lowe, Li-An K Brown, Kashfia Chowdhury, et al.
Frontiers in Immunology|July 26, 2024
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023)Samya Van Coillie, Johan Prévot, Silvia Sánchez-Ramón, et al.
The Journal of Allergy and Clinical Immunology|November 15, 2021
Treatment of chronic or relapsing COVID-19 in immunodeficiencyLi-An K Brown, Ed Moran, Anna Goodman, et al.
Clinical and Experimental Immunology|August 26, 2025
Immunophenotyping of apparently immunocompetent hosts with cryptococcosis reveals IL-17 deficiency as a unifying susceptibility factorKatie Townsend, Shichina Kannambath, Grant Hayman, et al.
Clinical Immunology (Orlando, Fla.)|January 13, 2024
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patientsAlexandra Y Kreins, Emma Roux, Juanita Pang, et al.
The Journal of Allergy and Clinical Immunology|August 16, 2019
A comprehensive characterization of chronic norovirus infection in immunodeficient hostsLi-An K Brown, Christopher Ruis, Ian Clark, et al.
Frontiers in Immunology|March 18, 2026
Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotypeAidan Jia Sheng Yu, Fernando Moreira, Andrew Symes, et al.
Frontiers in Immunology|October 10, 2022
Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experienceAdrian M Shields, Susan Tadros, Adam Al-Hakim, et al.
Journal of Clinical Immunology|April 14, 2022
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD StudyAdrian M Shields, Sian E Faustini, Harriet J Hill, et al.
The Journal of Infection|May 21, 2025
Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR studyJudith Breuer, Myriam Drysdale, Jill Walker, et al.
Pageof 10